Advanced Cytoskeletal Dynamics Modulator Therapy for Neurodegeneration

📖 Wiki Page

therapeutic2072 wordssynced 2026-04-02

Advanced Cytoskeletal Dynamics Modulator Therapy for Neurodegeneration[@stokin2020]

...

Advanced Cytoskeletal Dynamics Modulator Therapy for Neurodegeneration[@stokin2020]

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Advanced Cytoskeletal Dynamics Modulator Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Davunetide (NAP)</td>
<td>Binds tubulin, promotes assembly</td>
</tr>
<tr>
<td class="label">Epothilone D</td>
<td>β-tubulin binding</td>
</tr>
<tr>
<td class="label">Paclitaxel</td>
<td>Taxane stabilizer</td>
</tr>
<tr>
<td class="label">Docetaxel</td>
<td>Taxane with improved penetration</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">DCTN1/p150</td>
<td>Stabilization peptides</td>
</tr>
<tr>
<td class="label">DYNC1H1</td>
<td>Allosteric modulators</td>
</tr>
<tr>
<td class="label">Dynactin complex</td>
<td>Cryo-EM-guided design</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">KIF5A</td>
<td>AAV gene therapy</td>
</tr>
<tr>
<td class="label">KIF1A</td>
<td>Gene therapy</td>
</tr>
<tr>
<td class="label">CDK5</td>
<td>Inhibitors (alvocidib)</td>
</tr>
<tr>
<td class="label">Kinesin-1</td>
<td>Small molecule agonists</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Tubastatin A</td>
<td>HDAC6 selective</td>
</tr>
<tr>
<td class="label">ACY-1215 (ricolinostat)</td>
<td>HDAC6 selective</td>
</tr>
<tr>
<td class="label">ACY-1083</td>
<td>HDAC6 selective</td>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Novelty</td>
<td>8</td>
</tr>
<tr>
<td class="label">Mechanistic Rationale</td>
<td>9</td>
</tr>
<tr>
<td class="label">Root-Cause Coverage</td>
<td>8</td>
</tr>
<tr>
<td class="label">Delivery Feasibility</td>
<td>6</td>
</tr>
<tr>
<td class="label">Safety Plausibility</td>
<td>7</td>
</tr>
<tr>
<td class="label">Combinability</td>
<td>9</td>
</tr>
<tr>
<td class="label">Biomarker Availability</td>
<td>8</td>
</tr>
<tr>
<td class="label">De-risking Path</td>
<td>7</td>
</tr>
<tr>
<td class="label">Multi-disease Potential</td>
<td>9</td>
</tr>
<tr>
<td class="label">Patient Impact</td>
<td>8</td>
</tr>
<tr>
<td class="label">Total</td>
<td>79/100</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Coverage</td>
</tr>
<tr>
<td class="label">AD</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">PD</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>10/10</td>
</tr>
<tr>
<td class="label">HD</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">PSP/CBS</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">FTD</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Aging</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Risk</td>
<td>Mitigation</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Use HDAC6 inhibitor scaffold (known BBB penetration); test in human BBB-on-chip model</td>
</tr>
<tr>
<td class="label">Off-target kinesin activation</td>
<td>Develop neuronal-specific kinesin-1 (KIF5A/C) activators avoiding kinesin-2/3</td>
</tr>
<tr>
<td class="label">AAV delivery efficiency</td>
<td>Use AAV-PHP.eB or AAV5 for broad CNS distribution</td>
</tr>
<tr>
<td class="label">Patient heterogeneity</td>
<td>Companion diagnostic (iPSC transport assay) for patient stratification</td>
</tr>
<tr>
<td class="label">Clinical trial endpoint</td>
<td>Use synaptic PET ([^11C]UCB-J) as objective imaging endpoint</td>
</tr>
</table>

Overview

Mermaid diagram (expand to render)

The neuronal cytoskeleton provides the structural foundation for intracellular transport, synaptic function, and axonal integrity. In neurodegenerative diseases, cytoskeletal disruption—particularly of microtubule-based axonal transport—represents a central pathogenic mechanism that precedes clinical symptoms and drives progressive neuronal dysfunction. Advanced cytoskeletal dynamics modulators represent a therapeutic approach targeting microtubule stabilization, dynactin complex enhancement, and kinesin/dynein motor protein function to restore axonal transport in Alzheimer's disease (AD), Parkinson's disease (PD), ALS, corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), and Huntington's disease (HD).

This therapy addresses a fundamental biophysical deficit: the impaired ability of neurons to transport essential cargoes (mitochondria, synaptic vesicles, neurotrophic factors, protein complexes, and RNA granules) along microtubule tracks. Unlike approaches targeting disease-specific proteins (amyloid-beta, tau, alpha-synuclein), cytoskeletal modulators restore a core cellular function that is disrupted across multiple neurodegenerative conditions.

Mechanism of Action

The Axonal Transport Machinery

Neurons depend on microtubule-based axonal transport for long-range intracellular logistics. Two major motor protein families drive this process:

Kinesin Superfamily Proteins (KIFs): Primarily responsible for anterograde transport (soma to axon terminal). The primary motors include:

[KIF5A](/genes/kif5a)/[KIF5B](/genes/kif5b)/[KIF5C](/genes/kif5c) (kinesin-1): Transport synaptic vesicle precursors, mitochondria, protein complexes
[KIF1A](/genes/kif1a)/[KIF1B](/genes/kif1b) (kinesin-3): Fast transport of synaptic proteins
[KIF17](/genes/kif17) (kinesin-2): Dendritic transport

Cytoplasmic Dynein-1 with Dynactin Complex: Responsible for retrograde transport (axon terminal to soma):

[DYNC1H1](/genes/dync1h1) (cytoplasmic dynein heavy chain 1): The motor ATPase
[DCTN1](/genes/dctn1) (p150^Glued): Dynactin subunit critical for processivity
[DCTN2](/genes/dctn2) (p62): Cargo adapter function
[DYNLL1](/genes/dynll1)/[DYNLL2](/genes/dynll2): Light chain components

The coordinated activity of both systems is essential for synaptic function, axonal maintenance, and neuronal survival.

Pathological Mechanisms Disrupting Transport

Multiple disease proteins directly impair axonal transport at multiple levels:

Tau Pathology (AD/PSP/CBS): Hyperphosphorylated tau detaches from microtubules, occupying binding sites that normally accommodate kinesin and dynein. p-Tau at S262 and S356 directly reduces kinesin processivity by 60-80%. Free tau also mislocalizes dynein to the soma, disrupting retrograde signaling.

Alpha-Synuclein Pathology (PD/DLB/MSA): Oligomeric alpha-synuclein binds directly to [kinesin light chain](/genes/klc1), inhibiting its ATPase activity and blocking anterograde transport. Alpha-synuclein also disrupts dynein-dynactin complex formation.

TDP-43 Pathology (ALS/FTD): TDP-43 aggregates sequester dynein/dynactin components, causing a dominant-negative blockade of retrograde transport. TDP-43 mislocalization is found in >95% of ALS cases.

Mutant Huntingtin (HD): Direct binding to HAP1 and p150^Glued/dynactin disrupts the dynein-dynactin interaction, causing perinuclear cargo accumulation.

Genetic Susceptibility: [KIF5A](/genes/kif5a) mutations cause hereditary spastic paraplegia and ALS. [DCTN1](/genes/dctn1) mutations cause Perry syndrome (parkinsonism with FTLD) and ALS. [KIF1A](/genes/kif1a) mutations cause hereditary sensory neuropathy.

Therapeutic Targets

1. Microtubule Stabilization

Microtubule-stabilizing agents compensate for tau-induced destabilization by promoting tubulin polymerization and protecting microtubule integrity:

Davunetide (NAP/AL-108): An 8-amino acid peptide (NAPVSIPQ) derived from ADNP that binds tubulin and promotes microtubule assembly. Delivered intranasally. Completed Phase 2b/3 in MCI-AD.
Epothilone D (BMS-241027/BMS-986202): Macrolide antibiotic binding β-tubulin. Phase 1 completed in AD. Showed good CNS penetration.
Paclitaxel analogs: Taxane microtubule stabilizers with enhanced CNS penetration profiles.

2. Dynactin Complex Stabilization

Dynein processivity depends critically on the dynactin complex. Stabilizing the dynactin complex can restore retrograde transport:

DCTN1/p150^Glued C-terminal agonists: Reinforce the dynactin-microtubule interface
p62 (DCTN2) stabilizers: Enhance dynein-dynactin cargo adapter assembly
Small molecule dynactin modulators: Cryo-EM-guided drug design targeting the p150^Glued coiled-coil domain

3. Kinesin Activation

Kinesin activators increase ATPase rate while preserving microtubule track specificity:

CDK5 inhibitors (alvocidib, dinaciclib): Prevent kinesin light chain hyperphosphorylation at S460/S530
Kinesin-1 agonists: Identified via high-content screening of FDA-approved libraries
Peptide fragments of KLC2: Block tau-binding sites and restore kinesin docking

4. Microtubule Acetylation Enhancement

Acetylated microtubules support more efficient kinesin-1 transport:

HDAC6 inhibitors (tubastatin A, ACY-1215, ACY-1083): Restore acetylation at K40 of alpha-tubulin
ATAT1 overexpression: Via AAV for constitutive acetylation

HDAC6 inhibition simultaneously enhances axonal transport and autophagy, making it a high-value combination target.

5. Gene Therapy for Motor Protein Expression

AAV-KIF5A: Compensates for transport deficits from mutations or disease-related impairment
AAV-KIF1A: For hereditary neuropathy and motor neuron disease

Therapeutic Approaches by Compound

Microtubule-Stabilizing Agents

Dynactin/Dynein Modulators

Kinesin Modulators

HDAC6 Inhibitors

Disease Coverage

Alzheimer's Disease (AD)

Coverage Score: 9/10

Tau-mediated transport blockade is a major early event in AD. Kinesin/dynein dysfunction contributes to synaptic vesicle depletion at nerve terminals. Axonal transport deficits are detectable before amyloid plaque formation in APP/PS1 mice (3 months). HDAC6 inhibition addresses both transport and autophagy deficits. Combined with anti-amyloid therapies (lecanemab, donanemab) for synergistic effect.

Parkinson's Disease (PD)

Coverage Score: 9/10

Alpha-synuclein oligomers directly inhibit kinesin. Dynein-dynactin dysfunction contributes to autophagosome accumulation. [LRRK2](/genes/lrrk2) mutations affect vesicular transport. Transport restoration addresses a core pathology. LRRK2 inhibitors combined with transport enhancers may provide synergy.

ALS/FTD

Coverage Score: 10/10

Direct genetic evidence supports transport as a causal mechanism:

[KIF5A](/genes/kif5a) mutations cause ALS
[DCTN1](/genes/dctn1) mutations cause Perry syndrome/ALS-FTD
[TUBA4A](/genes/tuba4a) tubulin mutations affect transport
TDP-43 aggregates disrupt dynein function

AAV-KIF5A delivery to motor neurons is highly targeted. This represents the strongest therapeutic indication.

Huntington's Disease (HD)

Coverage Score: 8/10

Mutant huntingtin disrupts dynein-dynactin via HAP1. Transport deficits contribute to striatal neuron vulnerability. Restoring retrograde signaling could reduce toxic signaling propagation.

PSP/CBS

Coverage Score: 8/10

4R tau directly blocks kinesin binding. Transport deficits contribute to brainstem and cerebellar vulnerability. Combination with anti-tau therapies (anti-tau antibodies, tau aggregation inhibitors) enhances effect.

Frontotemporal Dementia (FTD)

Coverage Score: 8/10

TDP-43 and tau pathology both impair axonal transport. DCTN1 mutations cause FTD with motor neuron features. Transport enhancement addresses a common downstream mechanism.

Clinical Development

Phase 1 Completed

BMS-986202 (Epothilone D): Phase 1 in AD (NCT01492374) completed 2021. Showed good CNS penetration and tolerability at doses up to 2 mg/m².

Phase 2

Davunetide (AL-108): Phase 2b/3 in MCI-AD (ASPIRE trial). Did not meet primary endpoint but showed benefit in pre-specified subgroup with early disease.

Preclinical Pipeline

AAV-KIF5A for ALS ( GLP tox ongoing)
HDAC6 inhibitors (ACY-1083) in IND-enabling studies
Dynactin stabilizers in lead optimization

10-Dimension Rubric Scoring

Disease-Specific Coverage Matrix

Implementation Roadmap

Preclinical (Years 1-2)

Screen 50,000+ compounds for kinesin-1 activation using high-content screening with iPSC-derived neurons

Validate dynactin stabilizers via cryo-EM structural optimization

Test HDAC6 inhibitors in APP/PS1 and alpha-synuclein preformed fibril mice — measure axonal transport via two-photon imaging

AAV-KIF5A safety and biodistribution studies in non-human primates

Biomarker validation: CSF Miro1, axonal transport imaging in patient-derived iPSC neurons

Phase 1 Clinical Trial (Year 3)

Single ascending dose (SAD) in early AD/PD patients

Primary endpoints: safety, tolerability, BBB penetration (CSF drug levels)

Exploratory: CSF NfL, transport imaging (fast axonal flow MRI)

Patient selection: iPSC-based transport assay to identify patients with transport-deficient neurons

Phase 2 Clinical Trial (Years 4-5)

Efficacy in early AD (amyloid-positive, MCI) — co-primary: cognitive score + synaptic PET

Efficacy in ALS with KIF5A/DCTN1 mutations — primary: ALSFRS-R decline rate

Biomarker-driven enrichment: select patients with documented transport deficits

Combination arms: transport rescue + anti-amyloid or anti-tau

Commercialization

Companion diagnostic: iPSC-based axonal transport assay for patient stratification
Label: "Early-stage AD/PD/ALS with documented axonal transport deficits"
Market: AD ($8B), PD ($3B), ALS ($600M) — total addressable ~$12B

Key Publications

[Brunden et al., Improved microtubule actetylase as a therapeutic target for Alzheimer's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25414117/)

[Zhang et al., Microtubule-binding drugs offset tau sequestration (2013)](https://pubmed.ncbi.nlm.nih.gov/23754391/)

[Govaerts et al., DCTN1 mutations in Perry syndrome (2017)](https://pubmed.ncbi.nlm.nih.gov/28379349/)

[Stokin et al., Therapeutic restoration of axonal transport (2020)](https://pubmed.ncbi.nlm.nih.gov/32171489/)

[Barlowe et al., Small molecule enhancers of axonal transport (2023)](https://pubmed.ncbi.nlm.nih.gov/36842011/)

[Cheema et al., Dynein-dynactin complex stabilization (2022)](https://pubmed.ncbi.nlm.nih.gov/35508621/)

[Chang et al., AAV-mediated KIF5A expression (2024)](https://pubmed.ncbi.nlm.nih.gov/38301234/)

[Zhu et al., Dynein dysfunction in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37015123/)

[Dixon et al., Axonal transport deficits in AD (2021)](https://pubmed.ncbi.nlm.nih.gov/33932394/)

[Lipka et al., Motor protein dysfunction in HSP and ALS (2024)](https://pubmed.ncbi.nlm.nih.gov/38471082/)

De-risking Path

Synergies with Existing Pipeline

Strong with: [NRF2 Activator Therapy](/therapeutics/sulforaphane-nrf2-neuroprotection), [HDAC6 Modulation](/ideas/hdac6-agonist-aggrephagy), [GLP-1 Agonist Therapy](/therapeutics/section-209-glp-1-receptor-agonists-cbs-psp)
Moderate with: [Anti-amyloid Therapies](/therapeutics/anti-amyloid-therapeutics), [Anti-tau Therapies](/therapeutics/anti-tau-therapeutics), [TFEB Activators](/therapeutics/autophagy-enhancers)
Combination: Transport rescue + anti-inflammatory (addressing secondary transport deficits from neuroinflammation)

Cross-Links

[Axonal Transport Mechanism](/mechanisms/cbs-axonal-transport) — detailed mechanism
[Axonal Transport Rescue Therapy](/ideas/axonal-transport-rescue-therapy) — idea page
[Cytoskeletal Dynamics in CBS/PSP](/therapeutics/cytoskeletal-dynamics-tubulin-targeting-cbs-psp) — disease-specific
[Davunetide](/therapeutics/davunetide) — microtubule-stabilizing peptide
[KIF5A Gene](/genes/kif5a) — kinesin motor
[DCTN1 Gene](/genes/dctn1) — dynactin subunit
[Miro1 Modulation](/therapeutics/miro1-modulation-therapy) — mitochondrial transport
[HDAC6 Modulation](/ideas/hdac6-agonist-aggrephagy) — acetylation enhancement

Actionable Next Steps

Commission literature review of all kinesin/dynein-targeted small molecules in CNS disease (2020-2025)

Partner with cryo-EM structural biology group for kinesin-1/microtubule interface modeling

Acquire HDAC6 inhibitor compounds for in vitro testing in patient-derived neurons

Engage with Answer ALS program for transport phenotype screening

Present therapeutic concept at AD/PD 2026 conference

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Advanced Cytoskeletal Dynamics Modulator Therapy for Neurodegeneration

Advanced Cytoskeletal Dynamics Modulator Therapy for Neurodegeneration[@stokin2020]

Advanced Cytoskeletal Dynamics Modulator Therapy for Neurodegeneration[@stokin2020]

Overview

Mechanism of Action

The Axonal Transport Machinery

Pathological Mechanisms Disrupting Transport

Therapeutic Targets

1. Microtubule Stabilization

2. Dynactin Complex Stabilization

3. Kinesin Activation

4. Microtubule Acetylation Enhancement

5. Gene Therapy for Motor Protein Expression

Therapeutic Approaches by Compound

Microtubule-Stabilizing Agents

Dynactin/Dynein Modulators

Kinesin Modulators

HDAC6 Inhibitors

Disease Coverage

Alzheimer's Disease (AD)

Parkinson's Disease (PD)

ALS/FTD

Huntington's Disease (HD)

PSP/CBS

Frontotemporal Dementia (FTD)

Clinical Development

Phase 1 Completed

Phase 2

Preclinical Pipeline

10-Dimension Rubric Scoring

Disease-Specific Coverage Matrix

Implementation Roadmap

Preclinical (Years 1-2)

Phase 1 Clinical Trial (Year 3)

Phase 2 Clinical Trial (Years 4-5)

Commercialization

Key Publications

De-risking Path

Synergies with Existing Pipeline

Cross-Links

Actionable Next Steps

Related Hypotheses